Free Trial

Arcutis Biotherapeutics (ARQT) SEC Filings & 10K Form

$7.24
-0.36 (-4.74%)
(As of 06/7/2024 08:51 PM ET)

Recent Arcutis Biotherapeutics SEC Filings

DateFilerForm TypeView
06/04/2024
1:03 PM
Arcutis Biotherapeutics (Subject)
Welgus Howard G. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/31/2024
3:50 PM
Arcutis Biotherapeutics (Issuer)
Burnett Patrick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/30/2024
2:39 PM
Arcutis Biotherapeutics (Subject)
Burnett Patrick (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/29/2024
6:38 PM
Arcutis Biotherapeutics (Issuer)
Matsuda Masaru (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2024
4:12 PM
Arcutis Biotherapeutics (Issuer)
Edwards Larry Todd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/17/2024
2:58 PM
Arcutis Biotherapeutics (Subject)
Edwards Larry Todd (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/14/2024
3:08 PM
Arcutis Biotherapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/14/2024
3:06 PM
Arcutis Biotherapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/02/2024
2:27 PM
Arcutis Biotherapeutics (Subject)
Burnett Patrick (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/02/2024
2:28 PM
Arcutis Biotherapeutics (Subject)
Matsuda Masaru (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/02/2024
2:29 PM
Arcutis Biotherapeutics (Subject)
Moore Matthew Richard (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/02/2024
2:31 PM
Arcutis Biotherapeutics (Subject)
Watanabe Todd Franklin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/11/2024
7:30 PM
Arcutis Biotherapeutics (Issuer)
Topper David Joseph (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
04/11/2024
7:32 PM
Arcutis Biotherapeutics (Issuer)
Topper David Joseph (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/10/2024
3:15 PM
Arcutis Biotherapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/06/2024
4:12 PM
Arcutis Biotherapeutics (Issuer)
Burnett Patrick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2024
4:14 PM
Arcutis Biotherapeutics (Issuer)
Matsuda Masaru (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2024
4:08 PM
Arcutis Biotherapeutics (Issuer)
Moore Matthew Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2024
4:09 PM
Arcutis Biotherapeutics (Issuer)
Watanabe Todd Franklin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2024
11:40 AM
Arcutis Biotherapeutics (Subject)
Frazier Life Sciences VIII, L.P. (Filed by)
Form SC 13D/A
03/06/2024
9:31 AM
Arcutis Biotherapeutics (Subject)
JENNISON ASSOCIATES LLC (Filed by)
Form SC 13G/A
03/04/2024
4:44 PM
Arcutis Biotherapeutics (Subject)
OSBORNE DAVID W (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2024
4:47 PM
Arcutis Biotherapeutics (Subject)
Watanabe Todd Franklin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2024
4:38 PM
Arcutis Biotherapeutics (Subject)
Burnett Patrick (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2024
4:40 PM
Arcutis Biotherapeutics (Subject)
Matsuda Masaru (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2024
4:42 PM
Arcutis Biotherapeutics (Subject)
Moore Matthew Richard (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/28/2024
3:21 PM
Arcutis Biotherapeutics (Filer)
Form 424B5
02/27/2024
3:34 PM
Arcutis Biotherapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/27/2024
6:48 AM
Arcutis Biotherapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/27/2024
6:44 AM
Arcutis Biotherapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/15/2024
5:36 PM
Arcutis Biotherapeutics (Issuer)
Burnett Patrick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/15/2024
5:47 PM
Arcutis Biotherapeutics (Issuer)
Moore Matthew Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/15/2024
5:23 PM
Arcutis Biotherapeutics (Issuer)
Smither John W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/15/2024
5:30 PM
Arcutis Biotherapeutics (Issuer)
Watanabe Todd Franklin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/15/2024
5:32 PM
Arcutis Biotherapeutics (Issuer)
Matsuda Masaru (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/15/2024
3:19 PM
Arcutis Biotherapeutics (Subject)
Form SC TO-I/A
02/15/2024
3:20 PM
Arcutis Biotherapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/13/2024
11:29 AM
Arcutis Biotherapeutics (Subject)
SUVRETTA CAPITAL MANAGEMENT, LLC (Filed by)
Form SC 13G/A
02/13/2024
8:26 AM
Arcutis Biotherapeutics (Subject)
Polar Capital Holdings Plc (Filed by)
Form SC 13G/A
02/12/2024
8:52 AM
Arcutis Biotherapeutics (Subject)
MORGAN STANLEY (Filed by)
Form SC 13G
02/12/2024
5:06 AM
Arcutis Biotherapeutics (Subject)
Rubric Capital Management LP (Filed by)
Form SC 13G
It's time to ween off Chinese lithium! (Ad)

As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closely

Learn how this American company is leading the lithium-ion revolution
02/08/2024
11:15 PM
Arcutis Biotherapeutics (Filer)
Form EFFECT
02/08/2024
11:52 AM
Arcutis Biotherapeutics (Subject)
JENNISON ASSOCIATES LLC (Filed by)
Form SC 13G
01/31/2024
4:22 PM
Arcutis Biotherapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
01/29/2024
2:26 PM
Arcutis Biotherapeutics (Subject)
BlackRock Inc. (Filed by)
Form SC 13G
01/23/2024
9:26 AM
Arcutis Biotherapeutics (Subject)
STATE STREET CORP (Filed by)
Form SC 13G/A
01/17/2024
3:28 PM
Arcutis Biotherapeutics (Issuer)
Moore Matthew Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
3:30 PM
Arcutis Biotherapeutics (Issuer)
Watanabe Todd Franklin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
3:32 PM
Arcutis Biotherapeutics (Issuer)
Matsuda Masaru (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
3:34 PM
Arcutis Biotherapeutics (Issuer)
Edwards Larry Todd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2024
3:35 PM
Arcutis Biotherapeutics (Issuer)
Burnett Patrick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2024
5:03 AM
Arcutis Biotherapeutics (Subject)
Form SC TO-I
01/03/2024
4:30 PM
Arcutis Biotherapeutics (Issuer)
Burnett Patrick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/02/2024
1:29 PM
Arcutis Biotherapeutics (Subject)
Burnett Patrick (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/22/2023
4:24 PM
Arcutis Biotherapeutics (Issuer)
Watanabe Todd Franklin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/22/2023
2:26 PM
Arcutis Biotherapeutics (Subject)
Turney Patricia A. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/18/2023
5:33 AM
Arcutis Biotherapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/01/2023
7:51 PM
Arcutis Biotherapeutics (Issuer)
Watanabe Todd Franklin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/29/2023
2:51 PM
Arcutis Biotherapeutics (Subject)
Burrows Scott L (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/21/2023
4:47 PM
Arcutis Biotherapeutics (Issuer)
Matsuda Masaru (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/21/2023
2:36 PM
Arcutis Biotherapeutics (Subject)
Matsuda Masaru (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/16/2023
12:13 PM
Arcutis Biotherapeutics (Subject)
Polar Capital Holdings Plc (Filed by)
Form SC 13G
11/13/2023
8:02 AM
Arcutis Biotherapeutics (Subject)
FMR LLC (Filed by)
Form SC 13G/A
11/09/2023
1:54 PM
Arcutis Biotherapeutics (Subject)
PRUDENTIAL FINANCIAL INC (Filed by)
PRUDENTIAL FINANCIAL INC (Filed by)
Form SC 13G
11/07/2023
2:33 PM
Arcutis Biotherapeutics (Subject)
BlackRock Inc. (Filed by)
Form SC 13G/A
11/03/2023
6:32 AM
Arcutis Biotherapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/03/2023
6:36 AM
Arcutis Biotherapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/23/2023
3:23 PM
Arcutis Biotherapeutics (Filer)
Form 424B5
10/23/2023
3:25 PM
Arcutis Biotherapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/19/2023
3:02 PM
Arcutis Biotherapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/19/2023
3:15 PM
Arcutis Biotherapeutics (Filer)
Form 424B5
10/03/2023
8:45 PM
Arcutis Biotherapeutics (Issuer)
Edwards Larry Todd (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2023
8:41 PM
Arcutis Biotherapeutics (Issuer)
Edwards Larry Todd (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/27/2023
3:30 PM
Arcutis Biotherapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/15/2023
3:07 PM
Arcutis Biotherapeutics (Filer)
Form 10-K/A
09/15/2023
3:08 PM
Arcutis Biotherapeutics (Filer)
Form 10-Q/A
09/15/2023
3:09 PM
Arcutis Biotherapeutics (Filer)
Form 10-Q/A
09/12/2023
6:39 AM
Arcutis Biotherapeutics (Issuer)
Moore Matthew Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/07/2023
5:48 AM
Arcutis Biotherapeutics (Filer)
Form 8-K/A
09/05/2023
8:36 PM
Arcutis Biotherapeutics (Issuer)
Smither John W (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/05/2023
8:38 PM
Arcutis Biotherapeutics (Issuer)
Smither John W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2023
11:24 AM
Arcutis Biotherapeutics (Issuer)
Burnett Patrick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/21/2023
9:58 AM
Arcutis Biotherapeutics (Subject)
Burnett Patrick (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/18/2023
3:32 PM
Arcutis Biotherapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/15/2023
3:31 PM
Arcutis Biotherapeutics (Subject)
Lock Kenneth A. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/14/2023
4:22 PM
Arcutis Biotherapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:ARQT) was last updated on 6/10/2024 by MarketBeat.com Staff

From Our Partners